Chimeric fusion proteins - Diphtheria toxin-based

Current Opinion in Investigational Drugs

Volumn 2, Issue 9, 2001, Pages 1294-1301

  Frankel, A E ^a   Powell, B L ^a   Vallera, D A ^a   Neville D M , Jr ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cell surface receptors; Diphtheria toxin; Fusion proteins; Immunotoxins; Receptor mediated endocytosis; Toxin conjugates

Indexed keywords

(DIPHTHERIA TOXIN 390 S FV CYSTEINE)2; A DM DIPHTHERIA TOXIN 390 BIS FV; ANTINEOPLASTIC AGENT; CD90 ANTIBODY CRM; CELL SURFACE RECEPTOR; DAB 389 ALPHA INTERMEDIN; DAB 389 CD4 ANTIGEN; DAB 389 EPIDERMAL GROWTH FACTOR; DAB 389 GRP; DAB 389 INTERLEUKIN 6; DAB 389 INTERLEUKIN 7; DAB 389 NEUROTROPHIN; DAB 389 S INTERLEUKIN 15; DAB 390 VASCULOTROPIN 165; DENILEUKIN DIFTITOX; DENILEUKIN DIFTITOX PLUS BEXORETENE; DIPHTHERIA TOXIN; DIPHTHERIA TOXIN 388 GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; DIPHTHERIA TOXIN 388 INTERLEUKIN 3; DIPHTHERIA TOXIN 389 INTERLEUKIN 4; DIPHTHERIA TOXIN 389 NEU DIFFERENTIATION FACTOR; DIPHTHERIA TOXIN 390 N TERM URO; HYBRID PROTEIN; IMMUNOTOXIN; MILODISTIM; TRANSFERRIN CRM 107; TRANSFERRIN CRM 107 PLUS CHLOROQUINE; TRH CRM 45; UNCLASSIFIED DRUG;

CANCER; CATALYSIS; CELL DIVISION; CHIMERA; CLINICAL TRIAL; CONJUGATE; DRUG BINDING; DRUG SYNTHESIS; ENDOCYTOSIS; GENETIC ANALYSIS; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACEUTICAL ENGINEERING; PROTEIN SYNTHESIS; REVIEW; STRUCTURE ANALYSIS; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; DIPHTHERIA TOXIN; HUMANS; NEOPLASMS; RECOMBINANT FUSION PROTEINS;

EID: 0034835544     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. The crystal structure of diphtheria toxin
2. Expression cloning of a diphtheria toxin receptor: Identity with a heparin-binding EGF-like growth factor precursor
3. Expression of mutant dynamin protects cells against diphtheria toxin but not against ricin
4. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases
5. Penetration of protein toxins into cells
6. ADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis products
7. Immunotoxin-induced apoptosis
8. Artificial hybrid protein containing a toxic protein fragment and a cell membrane receptor-binding moiety in a disulfide conjugate
9. Receptor-mediated transport of the hybrid protein ricin-diphtheria toxin fragment A with subsequent ADP-ribosylation of intracellular elongation factor II
10. Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic
11. Asialoglycoprotein receptor mediates the toxic effects of an asialofetuin-diphtheria toxin fragment A conjugate on cultured rat hepatocytes
12. Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan and melanoma cells suppress in vivo tumor growth
13. Antibody-directed cytotoxic agents: Use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells
14. A comparative study of ricin and diphtheria toxin-antibody conjugate kinetics on protein synthesis inactivation
15. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity
16. Antitumor effects of antibody-diphtheria toxin conjugates. II. Immunotherapy with conjugates directed against tumor antigens induced by simian virus 40
17. Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related α-melanocyte-stimulating hormone fusion protein
18. Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein
19. Cytotoxicity of a recombinant diphtheria toxin-granulocyte colony-stimulating factor fusion protein on human leukemic blast cells
20. Molecular modification of a recombinant anti-CD3ε-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model
21. In vivo T-cell ablation by a holo-immunotoxin directed at human CD3
22. Structure function analysis of IL-2 toxin (DAB486IL-2): Fragment B sequences required for the delivery of fragment A to the cytosol of target cells
23. Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: A potential vector for delivering heterologous proteins to neurons
24. Diphtheria toxin-related α-melanocyte-stimulating hormone fusion toxin
25. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor
26. 389-IL-4)
27. 389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins
28. Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin β1
29. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for phase I clinical trials
30. Diphtheria toxin receptor binding domain substitution with interleukin-6: Genetic construction and interleukin-6 receptor specific action of a diphtheria toxin-related interleukin-6 fusion protein
31. 389 IL-7: A novel agent for the elimination of IL-7 receptor positive cells
32. 389sIL-15
33. A recombinant diphtheria toxin related human CD4 fusion protein specifically kills HIV infected cells which express gp120 but selects fusion toxin resistant cells which carry HIV
34. Genetic construction and properties of a diphtheria toxin-related substance P fusion protein: In vitro destruction of cells bearing substance P receptors
35. 389GRP
36. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells
37. Thyrotropin-releasing hormone-diphtheria toxin-related polypeptide conjugates: Potential role of the hydrophobic domain in toxin entry
38. Synthesis and cytotoxic profile of a diphtheria toxin-neurotrophin-4 chimera
39. Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia
40. Expression of an anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin in a mutant CHO cell line
41. Influence of endogenous Thy1.1 cells upon the efficacy of an anti-Thy1.1 antibody-diphtheria toxin conjugate
42. Selective destruction by diphtheria toxin conjugated to antibody directed against antigens on the cells
43. Protein engineering of diphtheria toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells
44. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion
45. Antibody-mediated routing of diphtheria toxin in murine cells results in a highly efficacious immunotoxin
46. Chimer toxins: Toxic, disulfide-linked conjugate of conconavalin A with fragment A from diphtheria toxin
47. Guinea pig line 10 hepatocarcinoma model: Characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain
48. Preparation of an immunotoxin for Acanthomoeba castellanii
49. An antibody-toxin conjugate directed against a human mammary cancer antigen
50. Enhancement of immunotoxin efficacy by acid-cleavable cross-linking agents utilizing diphtheria toxin and toxin mutants
51. Tumor regression with regional distribution of the targeted toxin Tf-CRM107 in patients with malignant brain tumors
52. Phase II trial of convection-enhanced distribution of recombinant immunotoxin in patients with recurrent malignant gliomas
53. 389EGF in patients with solid malignancies that express EGF receptors (EGFr)
54. Diphtheria toxin fusion proteins
55. Resistant acute myeloid leukemia responds to a novel diphtheria toxin/GM-CSF fusion protein: Summary of an ongoing phase I trial
56. 486IL-2) in hematologic malignancies: Complete response in a patient with Hodgkin's disease refractory to chemotherapy
57. 486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies
58. 486IL-2 in hematologic cancers
59. 486IL-2) in hematologic malignancies expressing the IL-2 receptor
60. 486IL-2 in advanced mycosis fungoides and the Sezary syndrome: Correlation of activity and interleukin-2 receptor expression in a phase II study
61. 389IL-2) in lymphomas expressing the receptor for interleukin-2
62. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma
63. Combination of ONTAK and steroids is associated with a significantly improved response rate in refractory CTCL
64. Treatment of relapsed refractory peripheral T-cell lymphoma with denileukin diftitox (Ontak): A case report of one patient
65. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107
66. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony-stimulating factor (GM) for the treatment of acute myeloid leukemia
67. Pharmacologic and immunologic studies of a diphtheria fusion protein in patients with relapsed or refractory AML
68. Kinetic analysis of ligand binding to interleukin-2 receptor complexes created on an optical biosensor surface
69. Ontak package insert
70. 389EGF fusion toxin on human glioblastoma cells
71. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein
72. A diphtheria toxin-interleukin-3 fusion protein is cytotoxic to acute myeloid leukemia (AML) stem cells but spares normal progenitors